^
PBRM1 mutation
Clear Cell Renal Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
Eur Urol - 2 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
sunitinib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pazopanib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
tivozanib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
bevacizumab + pegylated interferon α -2a
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
avelumab + axitinib
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
temsirolimus
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
sorafenib
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
lenvatinib
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
axitinib
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
everolimus
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
bevacizumab
Sensitive: A2 - Guideline
PD-L1 expression
Clear Cell Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive: B - Late Trials
VHL mutation
Clear Cell Renal Cell Carcinoma
belzutifan
Sensitive: C1 - Off-label
VHL mutation
Clear Cell Renal Cell Carcinoma
PT2385
Sensitive: C2 – Inclusion Criteria
SETD2 mutation
Clear Cell Renal Cell Carcinoma
Immunotherapy
Resistant: C3 – Early Trials
ERVE-4 expression
Clear Cell Renal Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
SYNE1 mutation
Clear Cell Renal Cell Carcinoma
Immunotherapy
Sensitive: C3 – Early Trials
HMOX1 expression
Clear Cell Renal Cell Carcinoma
sunitinib
Sensitive: C3 – Early Trials
CDKN2A mutation
Clear Cell Renal Cell Carcinoma
palbociclib
Sensitive: C3 – Early Trials
HMOX1 expression
Clear Cell Renal Cell Carcinoma
sorafenib
Sensitive: C3 – Early Trials
VHL mutation
Clear Cell Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
VHL promoter methylation
Clear Cell Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
EPAS1 overexpression
Clear Cell Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
HIF1A expression
Clear Cell Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
MCAM overexpression
Clear Cell Renal Cell Carcinoma
sunitinib
Resistant: C3 – Early Trials
KDR C482R
Clear Cell Renal Cell Carcinoma
crizotinib + pazopanib
Sensitive: C3 – Early Trials
DDX39B overexpression
Clear Cell Renal Cell Carcinoma
Immunotherapy
Resistant: C3 – Early Trials
AXL overexpression
Clear Cell Renal Cell Carcinoma
nivolumab
Resistant: C3 – Early Trials
AXL overexpression + PD-L1 expression
Clear Cell Renal Cell Carcinoma
nivolumab
Resistant: C3 – Early Trials
CTLA4 promoter hypomethylation
Clear Cell Renal Cell Carcinoma
PD1 inhibitor
Sensitive: C3 – Early Trials
TP53 mutation
Clear Cell Renal Cell Carcinoma
sunitinib
Resistant: C3 – Early Trials
NANOGNB mutation
Clear Cell Renal Cell Carcinoma
Immunotherapy
Sensitive: C3 – Early Trials
CXCL13 elevation
Clear Cell Renal Cell Carcinoma
nivolumab
Resistant: C3 – Early Trials
TNFSF13B elevation
Clear Cell Renal Cell Carcinoma
nivolumab
Resistant: C3 – Early Trials
IL6 elevation
Clear Cell Renal Cell Carcinoma
nivolumab
Resistant: C3 – Early Trials
MTOR Q2223K
Clear Cell Renal Cell Carcinoma
everolimus
Sensitive: C4 – Case Studies
MET fusion
Clear Cell Renal Cell Carcinoma
cabozantinib tablet
Sensitive: C4 – Case Studies
DAPK1 underexpression
Clear Cell Renal Cell Carcinoma
sunitinib
Resistant: D – Preclinical
PTTG1 overexpression
Clear Cell Renal Cell Carcinoma
NSC23766
Sensitive: D – Preclinical
CXCR4 overexpression
Clear Cell Renal Cell Carcinoma
cisplatin
Resistant: D – Preclinical